Countable Labs

Executive Summary

Countable Labs is a San Francisco-based biotechnology company pioneering a novel PCR technology, Countable PCR, which enables true single-molecule DNA quantification. Unlike traditional quantitative PCR (qPCR) or digital PCR (dPCR), Countable PCR offers unmatched sensitivity, precision, and a broad dynamic range, making it a superior platform for genomics research and diagnostics. Founded in 2018, the company aims to address critical limitations in nucleic acid quantification, with potential applications in liquid biopsy, infectious disease testing, and rare variant detection. The company's technology has the potential to disrupt the $5 billion PCR diagnostics market by providing more accurate and reliable quantification. Early validation and partnerships will be key to commercial traction. With its differentiated approach, Countable Labs is well-positioned to capture market share in both research and clinical settings. However, the company remains in a relatively early stage, with no disclosed funding or revenue. Successful execution will depend on securing capital, obtaining regulatory clearances, and forming strategic alliances with diagnostic leaders.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Announcement70% success
• Q1 2027Partnership with Major Diagnostics Company50% success
• Q4 2026Publication of Clinical Validation Data in Peer-Reviewed Journal60% success